Investors

Home / Investors / Press Releases
26Jun

CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance

11May

CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update

4May

CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11

13Apr

CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017

30Mar

CymaBay Therapeutics to Present at Two Investor Conferences in April

29Mar

CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.

23Mar

CymaBay Reports Fourth Quarter and Year End 2016 Financial Results

16Mar

CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23

9Mar

CymaBay Therapeutics to Present at Two Investor Conferences in March

7Feb

CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference

2Feb

CymaBay Announces Pricing of Public Offering of Common Stock

1Feb

CymaBay Announces Proposed Public Offering of Common Stock

5Jan

CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

3Jan

CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States

8Dec

CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors

7Dec

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis

6Dec

CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar

28Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

10Nov

CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City

10Nov

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis

9Nov

CymaBay Reports Third Quarter 2016 Financial Results

9Nov

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)

2Nov

CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

20Oct

CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis

11Oct

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

6Oct

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting

5Oct

CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis

8Sep

CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

9Aug

CymaBay Reports Second Quarter 2016 Financial Results

2Aug

CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9

7Jul

CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York

31May

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)

19May

CymaBay Therapeutics to Present at UBS Global Healthcare Conference

11May

CymaBay Reports First Quarter 2016 Financial Results

2May

CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11

29Mar

CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results

28Mar

CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors

28Mar

CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology

22Mar

CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors

21Mar

CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29

17Mar

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

3Mar

CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March

2Feb

CymaBay Therapeutics to Present at the BIO CEO & Investor Conference

20Jan

CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate

6Jan

CymaBay Therapeutics to Present at the Biotech Showcase 2016

13Nov

CymaBay Announces Participation at Three Upcoming Investor Conferences

12Nov

CymaBay Announces Third Quarter Financial Results

10Nov

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis

5Nov

CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11

4Nov

CymaBay to Announce Third Quarter 2015 Financial Results on Thursday, November 12

8Oct

CymaBay Announces the Appointment of Robert J. Wills, Ph.D., as Chairman of the Board of Directors

3Sep

CymaBay Therapeutics to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

10Aug

CymaBay Announces Second Quarter 2015 Financial Results

6Aug

CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents

3Aug

CymaBay to Announce Second Quarter 2015 Financial Results on Monday, August 10

27Jul

CymaBay Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

15Jul

CymaBay Therapeutics Announces Pricing of $20 Million Public Offering of Common Stock

14Jul

CymaBay Announces Proposed Public Offering of Common Stock

6Jul

CymaBay Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference

12Jun

CymaBay Therapeutics Presents Poster at EULAR 2015

29May

CymaBay to Present at the Jefferies 2015 Global Healthcare Conference

15May

CymaBay to Present at the 2015 UBS Global Healthcare Conference

7May

CymaBay Reports First Quarter 2015 Financial Results

1May

CymaBay to Announce First Quarter 2015 Financial Results on Thursday, May 7, 2015

23Apr

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia

22Apr

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia

20Apr

CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance

7Apr

CymaBay to Present at the 14th Annual Needham Healthcare Conference

25Mar

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia

24Mar

CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors

23Mar

CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City

18Mar

CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results

11Mar

CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015

27Feb

CymaBay to Present at Upcoming Investor Conferences

24Feb

CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares

4Feb

CymaBay to Present at 17th Annual BIO CEO & Investor Conference

28Jan

CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia

12Jan

Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat

26Nov

CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference

12Nov

CymaBay Reports Third Quarter 2014 Financial Results

31Oct

CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014

15Oct

CymaBay Therapeutics to Participate in Two Upcoming Investor Conferences

29Sep

CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout

28Jul

CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22Jul

CymaBay Therapeutics Announces Pricing of Public Offering of Common Stock

17Jul

CymaBay Therapeutics Announces Proposed Offering of Common Stock

16Jun

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"

2Jun

CymaBay Therapeutics to Present at Upcoming Conferences

26Mar

CymaBay Initiates Arhalofenate Phase 2b Gout Study

3Mar

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer

25Feb

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences

3Feb

CymaBay to Present at 16th Annual Bio CEO & Investor Conference

24Jan

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link

13Jan

Sujal Shah Appointed Chief Financial Officer of CymaBay Therapeutics

11Dec

CymaBay Therapeutics, Inc. Completes Financing

10Dec

Metabolex Undergoes Capital Restructure and Renames as CymaBay Therapeutics

8Dec

Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat

29Nov

Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch

1Nov

Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting

19May

Metabolex Initiates Phase 2 Trial of Arhalofenate

22Jun

Metabolex Enters Into Type 2 Diabetes Development and License Agreement

Press Releases Press Releases